{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-087756","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2026-08-11T20:00:21+00:00","discovered_at":"2026-08-11T20:01:00.590448+00:00","generated_at":"2026-08-11T20:01:06.985884+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TherapeuticsMD Q2 2026 net income $164K, revenue $869K; explores strategic alternatives","bullets":["Net income from continuing operations $164K vs $545K in Q2 2025; license revenue $869K vs $952K.","Total operating expenses $1.7M, up 2.3% YoY on higher G&A and patent write-off.","Cash and cash equivalents $9.2M as of June 30, 2026.","Company continues evaluating strategic alternatives including merger, sale, or other transactions; no timetable set."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-087756","json":"https://secwatch.observer/filing/0001213900-26-087756.json","markdown":"https://secwatch.observer/filing/0001213900-26-087756.md","text":"https://secwatch.observer/filing/0001213900-26-087756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/0001213900-26-087756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/ea0298979-8k_therapeu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:01:06.985884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}